MET and glioblastoma: Information on immunogenic HLA-II peptides in GBM is very limited, and among the few immunogenic HLA-II epitopes reported so far, that have been included in the GAPVAC and IMA950 trials, are from brevican core protein (BCAN), Survivin (BIRC5), Receptor-type tyrosine-protein phosphatase zeta (PTPRZ1), and MET.